Citizens Jmp Has Lowered Expectations for Integra LifeSciences (NASDAQ:IART) Stock Price

Integra LifeSciences (NASDAQ:IART) had its target price dropped by research analysts at Citizens Jmp from $25.00 to $22.00 in a report released on Thursday, Benzinga reports. The brokerage presently has a “market outperform” rating on the life sciences company’s stock. Citizens Jmp’s price target suggests a potential upside of 84.49% from the company’s previous close.

IART has been the topic of several other reports. UBS Group initiated coverage on shares of Integra LifeSciences in a report on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 price target on the stock. BMO Capital Markets restated a “market perform” rating on shares of Integra LifeSciences in a report on Thursday. Weiss Ratings cut Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd. Wall Street Zen downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Finally, JPMorgan Chase & Co. lowered their target price on Integra LifeSciences from $17.00 to $14.00 and set an “underweight” rating on the stock in a research note on Thursday. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $17.25.

Integra LifeSciences Stock Performance

IART traded up $0.09 during trading hours on Thursday, reaching $11.93. The company’s stock had a trading volume of 284,433 shares, compared to its average volume of 909,438. The company’s 50-day moving average is $15.56 and its 200-day moving average is $15.56. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $20.49. The firm has a market cap of $927.41 million, a PE ratio of -132.37, a price-to-earnings-growth ratio of 0.71 and a beta of 1.21. The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, October 21st. The life sciences company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.03. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The firm had revenue of $411.18 million during the quarter, compared to analysts’ expectations of $413.16 million. During the same period in the previous year, the business posted ($0.07) earnings per share. On average, equities analysts forecast that Integra LifeSciences will post 2.39 EPS for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently modified their holdings of the business. Public Employees Retirement System of Ohio bought a new position in Integra LifeSciences during the second quarter worth about $82,000. Integrated Wealth Concepts LLC acquired a new stake in Integra LifeSciences in the 2nd quarter worth about $84,000. Sequoia Financial Advisors LLC boosted its holdings in Integra LifeSciences by 27.4% in the 1st quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock valued at $134,000 after purchasing an additional 3,059 shares during the period. Amundi boosted its holdings in Integra LifeSciences by 80.8% in the 1st quarter. Amundi now owns 19,430 shares of the life sciences company’s stock valued at $183,000 after purchasing an additional 8,681 shares during the period. Finally, Corient Private Wealth LP boosted its holdings in Integra LifeSciences by 66.9% in the 2nd quarter. Corient Private Wealth LP now owns 22,749 shares of the life sciences company’s stock valued at $409,000 after purchasing an additional 9,120 shares during the period. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences News Summary

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Adjusted earnings beat estimates: Integra reported third-quarter adjusted EPS of $0.59, above the $0.56 consensus and up from $0.54 a year earlier. GAAP EPS improved to $0.19 from a $0.07 loss, while operating cash flow reached $96 million. Integra LifeSciences Surpasses Q3 Earnings Estimates
• Positive Sentiment: Debt refinancing reduces near-term maturity risk: Integra completed a $2.1 billion refinancing that extends maturities and provides additional covenant capacity. Net debt declined to approximately $1.52 billion, and the leverage ratio fell to 3.8x. However, the company expects interest expense to increase toward the high end of its previously forecast 100-to-200-basis-point range. Integra LifeSciences Refinancing
• Neutral Sentiment: Revenue grew modestly: Third-quarter revenue increased 2.3% year over year to $411.2 million, broadly near expectations. Specialty Surgery revenue rose 3.9%, led by neurosurgery, while the company maintained its full-year 2026 revenue and adjusted EPS guidance of $1.634 billion–$1.654 billion and $2.30–$2.40, respectively. Integra Reports Third-Quarter Results
• Negative Sentiment: Weak outlook and operating disruptions weigh on shares: Integra forecast fourth-quarter revenue of $413 million–$433 million, implying a year-over-year decline of up to 5.2%. Cincinnati flood damage reduced quarterly revenue by about $7 million, while Tissue Reconstruction revenue fell 2.2% and adjusted gross margin declined to 61.1% from 62.9%. Integra Falls as Tissue Reconstruction Woes Add to Flooding Worries
• Negative Sentiment: Analyst sentiment deteriorated: JPMorgan lowered its price target from $17 to $14 and assigned an “underweight” rating. Truist also reduced its target from $19 to $15, reinforcing concerns about slower growth and execution. JPMorgan Cuts Integra Price Target
• Negative Sentiment: Legal overhang remains: Kirby McInerney LLP said it is continuing an investigation into potential securities-law violations and other alleged misconduct involving Integra and senior management, adding reputational and litigation risk. Integra Investor Investigation

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.